Claims for Patent: 8,821,867

Summary for Patent: 8,821,867

Title:	4-1BB binding molecules
Abstract:	The present disclosure provides isolated binding molecules that bind to human 4-1BB, nucleic acid molecules encoding an amino acid sequence of the binding molecules, vectors comprising the nucleic acid molecules, host cells containing the vectors, methods of making the binding molecules, pharmaceutical compositions containing the binding molecules, and methods of using the binding molecules or compositions.
Inventor(s):	Ahrens; Bianca (Munich, DE), Baxi; Sangita M. (San Diego, CA), Fisher; Timothy Scott (San Diego, CA), Jerome; Richard Michael (East Hampstead, NH), Ladetzki-Baehs; Kathrin (Planegg, DE), Oliphant; Theodore (Galesburg, MI), Sharp; Leslie Lynne (San Diego, CA), Tesar; Michael (Augsberg, DE), Yates; Libbey Anne (Dardenne Prairie, MO), Zulley; Moritz (Munich, DE)
Assignee:	Pfizer Inc (New York, NY)
Application Number:	13/676,288
Patent Claims:	1. An isolated antibody or an antigen-binding portion thereof wherein said antibody or antigen-binding portion binds human 4-1BB extracellular domain at an epitope located within amino acid residues 115-156 of SEQ ID NO: 68. 2. The antibody or antigen-binding portion thereof according to claim 1 wherein said antibody or antigen-binding portion binds human 4-1BB with a K.sub.D of 10 nM or less for the human 4-1BB extracellular domain as measured using a surface plasmon resonance assay. 3. The antibody or antigen-binding portion thereof according to claim 2 wherein said antibody or antigen-binding portion thereof comprises a V.sub.H and a V.sub.L region wherein the V.sub.H region amino acid sequence is set forth in SEQ ID NO: 43 and the V.sub.L region amino acid sequence is set forth in SEQ ID NO: 45. 4. A pharmaceutical composition comprising an antibody or antigen-binding portion thereof according to claim 1 and a pharmaceutically acceptable carrier. 5. A method for reducing tumor growth in a subject in need thereof, comprising administering to the subject an effective amount of an antibody or antigen-binding portion thereof according to claim 1, and a pharmaceutically acceptable carrier. 6. A method of treating cancer in a mammal, which comprises administering to the mammal in need of treatment a therapeutically effective amount of an antibody or antigen-binding portion thereof according to claim 1, and a pharmaceutically acceptable carrier. 7. The method of claim 6 wherein said cancer is selected from the group consisting of colorectal cancer, non-Hodgkin's lymphoma, prostate cancer, or melanoma. 8. A method of treating cancer in a mammal which comprises administering to the mammal a therapeutically effective amount of an antibody or antigen-binding portion thereof according to claim 3 in combination with an immunotherapeutic agent. 9. The method of claim 8 wherein said immunotherapeutic agent is rituximab. 10. A method for reducing tumor growth in a subject in need thereof, comprising administering to the subject an effective amount of an antibody or antigen-binding portion thereof according to claim 3, and a pharmaceutically acceptable carrier. 11. A method of treating cancer in a mammal, which comprises administering to the mammal in need of treatment a therapeutically effective amount of an antibody or antigen-binding portion thereof according to claim 3, and a pharmaceutically acceptable carrier. 12. The method of claim 11 wherein said cancer is selected from the group consisting of colorectal cancer, non-Hodgkin's lymphoma, prostate cancer, or melanoma. 13. A method of treating cancer in a mammal which comprises administering to the mammal a therapeutically effective amount of an antibody or antigen-binding portion thereof according to claim 1 in combination with an immunotherapeutic agent. 14. The method of claim 13 wherein said immunotherapeutic agent is rituximab.

Details for Patent 8,821,867

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	RITUXAN	rituximab	Injection	103705	11/26/1997		2031-09-09
Idec Pharmaceuticals Corp.	RITUXAN	rituximab	Injection	103737	02/19/2002		2031-09-09
Genentech, Inc.	RITUXAN HYCELA	rituximab and hyaluronidase human	Injection	761064	06/22/2017		2031-09-09